HEALTHCONN Business Summary

Healthconn Corp. (6665.TWO) is a Taiwan-based healthcare services provider specializing in precision medicine and integrated disease prevention. The company generates approximately 92% of its revenue through the trading of precision medical devices, supplemented by bio-safety testing and health service management fees. Its primary business segments include molecular diagnostics, cancer gene testing, health promotion consulting, and clinical microbiology solutions. Leveraging AI, big data, and genomic analysis, Healthconn maintains an integrated healthcare ecosystem serving both individual and corporate clients in Taiwan and mainland China. Within the regional market, it competes directly with CHC Healthcare Group (4164), Arich Enterprise (4173), and TCI GENE (6879), positioning itself as a technology-first player backed by the industrial scale of its parent group. Founded in 2009, Healthconn operates as a core subsidiary of the Foxconn Technology Group (Hon Hai Precision Industry). The company is currently led by President and CEO Bill Tsou, who also serves as a Director and brings extensive experience in technology-driven health management. The executive team and board are heavily influenced by Foxconn’s leadership pedigree, focusing on the intersection of electronics manufacturing and smart medical solutions. Major institutional investors include Hyield Venture Capital Co., Ltd., which maintains a 38% controlling interest, and Hon Hai Precision Industry Co., Ltd., which holds an 11.2% stake. This ownership structure provides Healthconn with significant capital stability and direct access to the global supply chain resources of its parent organization.